Why the study?
Does cyclophosphamide treatment increase persistent CNS infection following attenuated human poliovirus infection in mice?
Does cyclophosphamide treatment increase persistent CNS infection following attenuated human poliovirus infection in mice?
Cyclophosphamide treatment in mice infected with attenuated human poliovirus significantly increases the rate of persistent CNS infection.
Answers are grounded in this paper and cite their sources.
May increase persistent CNS infection risk under immunosuppression in this model; leaves open relevance to human poliovirus exposure or vaccines.
An attenuated human poliovirus infection of cyclophosphamide (CY)-treated mice resulted in a persistent CNS infection. Persistence in asymptomatic animals occurred in 46% of CY-treated mice but in only 3% of untreated animals, and was confined primarily to the brain. Virus replication in the brain peaked by day 3 for all inoculum dilutions, but was lower with diluted virus. High virus titers in the spinal cord were found only in paralyzed animals and occurred late in the infection following inoculation of diluted virus. Thus, the level of virus replication in the brain was directly related to the amount of virus inoculated, and was correlated with the rapidity of virus transit to the spinal cord and the incubation time to paralysis.
No takes yet. Share an insight, caveat, or question.
Jubelt et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: